A B S T R A C T Inhibition of complement-mediated granulocyte aggregation has recently been proposed as a mechanism of action of high-dose corticosteroids in shock states. Postulating that such inhibition might be effected through alteration of receptor function, we examined the effect of methylprednisolone (MP), hydrocortisone (HC), and dexamethasone (DEX) on the extent and kinetics of binding of the synthetic chemotaxin f-methionine-leucine-phenylalanine (FMLP) to its specific receptor on the granulocyte surface. Dosedependent inhibition of binding was observed at corticosteroid concentrations paralleling plasma levels achieved with 30 mg/kg intravenous bolus therapy; the order of potency was MP > HC > DEX. Receptor number was unaffected by steroid exposure, but the steroids effected a decrease in association rate constant for the FMLP-receptor interaction (35% of N for 0.2 mg/ml MP), leading to decreased receptor-ligand affinity. Dissociation kinetics, as examined by coldchase experiments, were unaltered by the corticosteroids. Furthermore, in addition to the inhibition of aggregation previously reported, aggregated granulocytes were found to disaggregate upon addition of corticosteroids; the order of potency was again MP > HC > DEX, with an MP concentration of -2-3 mglml required to effect complete disaggregation. We conclude that corticosteroids can displace FMLP from the granulocyte surface by slowing association while allowing dissociation to proceed; altered kinetics of receptor-FMLP interaction may explain both the inhibition of granulocyte aggregation and granulocyte disaggregation. If these observations also hold for physiologic stimuli (such as C5adesarginine, which behaves similarly with respect to aggregation, inhibition, and disaggregation), such kinetic changes may be important in the clinical effects of very high-dose corticosteroids such as are administered in shock.
INTRODUCTION
Complement activation may be associated with neutropenia in vivo and has been shown to cause granulocyte (PMN)l aggregation, both in vitro and in vivo (1, 2) . These phenomena, augmented by the stimulated PMN production of toxic oxygen compounds (3) , have been suggested to be important in the pathogenesis of a variety of clinical disorders. They include hemodialysis neutropenia and pulmonary dysfunction (1, 4, 5) , the vasculitis of cholesterol embolization syndrome (6) , and the adult respiratory distress syndrome (7) (8) (9) . Corticosteroids have been shown to blunt the PMN responses to activated complement components (10) , and the recent finding that high-dose corticosteroids inhibit granulocyte aggregation in vitro and in vivo (7, 11) suggested a possible mechanism for their reported efficacy in the adult respiratory distress syndrome and endotoxic shock (12) (13) (14) (15) (16) (17) (18) . High-dose cortico-1Abbreviations used in this paper: DEX, dexamethasone sodium phosphate; FMLP, N-formyl-methionine-leucinephenylalanine; HBSS, Hanks' balanced salt solution; HC, hydrocortisone sodium succinate; MP, methylprednisolone sodium succinate; PBS, phosphate-buffered saline; PMN, granulocyte. steroid therapy has also recently been tried in other diseases such as idiopathic rapidly progressive glomerulonephritis, and further trials are being contemplated (6, 19) .
Because corticosteroids have been reported to alter surface receptors in some immune adherence assays (20) (21) (22) (23) , we postulated altered receptor function as a possible mechanism of high-dose corticosteroid effect on granulocyte responses to activated complement components. This hypothesis has been studied using the synthetic chemotaxin N-formyl-methionine-leucinephenylalanine (FMLP) as a probe to study the effect of corticosteroids on PMN receptor function. Although its receptor is distinct from that for complement (C)5a (24) , FMLP mimics many of the effects of activated complement, including chemotaxis and aggregation of PMN, and in vivo induction of neutropenia (25) ; further, FMLP-induced PMN aggregation is inhibited by the same concentrations of corticosteroids that inhibit C5a-induced aggregation (7) . It is unclear from earlier studies whether the blunting effect of corticosteroids upon granulocytes' responses to FMLP and C5a is related to an effect upon the receptors for those agents. We therefore examined the effect of corticosteroids on the binding of FMLP to its specific surface receptors on granulocytes.
METHODS
Cell preparation. Granulocytes were prepared from heparinized human venous blood by the described modification of the method of Boyum (1, 26) . Cells were suspended at appropriate concentrations in a buffer solution, pH 7.2, consisting of 135 mM NaCl, 4.5 mM KCI, 1.3 g/liter dextrose, and 10 mM N-2-hydroxyethylpiperazine-N'2-ethanesulfonic acid (HEPES buffer) or in Hanks' balanced salt solution (HBSS) (M. A. Bioproducts, Bethesda, Md). Differential cell counts performed on Wright's stained cells revealed >95% PMN.
Preparation of solutions. Preservative and filler-free hydrocortisone sodium succinate (HC), methylprednisolone sodium succinate (MP) (Upjohn Co., Kalamazoo, Mich.), and dexamethasone sodium phosphate (DEX) (Merck Sharp & Dohme, West Point, Pa.) were kindly provided by the manufacturers and dissolved in isotonic phosphate-buffered saline (PBS), pH 7.4. FMLP (Peninsula Laboratories, Inc., San Carlos, Calif.) was dissolved in dimethylsulfoxide at 10 mM, diluted in PBS to 1 mM, and stored at -70°C until use.
Zymosan-activated plasma was prepared as described (1) by incubating 2 mg zymosan/ml ofheparinized (1 U/ml) human plasma for 30 min at 37°C, followed by removal of zymosan by centrifugation at 10,000 g for 30 min at 4°C. Aliquots were stored at -70°C until use. Disodium succinate, hydrocortisone-21-phosphate (Sigma Chemical Co., St. Louis, Mo.), 2-deoxy-D-glucose (Aldrich Chemical Co., Milwaukee, Wis.), and [3H]FMLP (sp act 56.9 Ci/mmol, New England Nuclear, Boston, Mass.) were dissolved in PBS at appropriate concentrations. Deoxyribonuclease (Worthington Biochemical Corp., Freehold, N. J.) was dissolved in 0.1 M NaCl (1 mg/ml) and kept at -70°C until use. Preparation of sonicated cell suspensions. PMN were suspended in HBSS at a concentration of 4 x 107/ml and sonicated for 30s in a Sonifier cell disruptor (model 350, Branson Sonic Power Co., Danbury, Conn.). The suspension was then centrifuged at 23,000 g for 20 min, and the pellet was resuspended in an appropriate volume of HBSS containing 1 Ag/ml DNAase. Microscopic examination of the suspensions revealed no intact PMN.
Preparation of glutaraldehyde-fixed cells. Granulocytes were fixed with glutaraldehyde as described (27) . Briefly, PMN were suspended at 108 cells/ml in PBS containing 0.5% bovine serum albumin (Sigma Chemical Co.) at room temperature and mixed with 1 vol of 0.25% glutaraldehyde in PBS. After 5 min the reaction was terminated by adding 0.5 vol of PBS containing 5% bovine serum albumin, and the cells were pelleted and resuspended in the appropriate buffer.
In vivo induction of neutropenia. New Zealand white rabbits were anesthetized with thiopental, and an ipsilateral femoral artery and vein were cannulated (5) . FMLP (10 ,uM in PBS) was infused into the inferior vena cava at a constant rate of 0.5 ml/min and arterial blood was sampled serially and heparinized (2 U/ml).
Kinetic analysis of the FMLP receptor interaction. Analysis of equilibrium binding of FMLP receptors was determined as described by Williams et al (24) with minor modifications. Cells were suspended in HBSS at 5-10 x 107 cells/ml. 100 ul of cell or sonicated cell suspension was mixed with 17 ,ul of corticosteroid or PBS and incubated for 2 min at room temperature; the cells were then added to 35 (28) (29) (30) , in which the relation ln[r/(lr)] = a In c + a In equilibrium binding constant (Keq) was plotted as ln[r(Ir)] vs. ln c, where r = (concentration of bound [3H]FMLP)/(total receptor concentration) and c = free [3H]FMLP concentration. Equilibrium binding data was also analyzed by the method of Scatchard (31) where r/c = Keq -r Keq.
Dissociation kinetics were determined by incubating 5 x 107 cells/ml with receptor saturating concentrations of [3H]FMLP in HBSS at 37°C for 15 min. DNAse (final concentration 1 jtg/ml) and either a large excess of unlabeled FMLP or methylprednisolone (final concentration 5 mg/ml) were then added in a small volume at t = 0, and at varying time intervals, aliquots were taken, filtered through a Whatman GF/C filter, washed with cold HBSS, and the filters were counted as described above. Simultaneous controls were performed in the presence of excess unlabeled FMLP to measure nonspecific binding. Parallel experiments were performed with the addition of sodium azide and 2-deoxy-D-glucose in order to block receptor-ligand complex internalization (32) . The resulting specific disintegrations per minute (dpm) were calculated, and the concentration of cellbound [3H]FMLP was analyzed assuming the relationship: (33) .
Association kinetics were determined by incubating cells in HBSS in the presence or absence of 0.2 mg/ml methylprednisolone for 2 min; [3H]FMLP was then added so that the initial [3H]FMLP concentration was at least 10 times the initial concentration of receptor sites (determined by equilibrium binding in the presence of excess [3H]FMLP). At varying time intervals samples were removed, filtered, washed, and counted as described. Although simultaneous experiments were performed in the presence of excess unlabeled FMLP to determine nonspecific binding, this correction was insignificant in most association experiments.
The rcsulting disintegrations per minute bound were calculated, and the concentrations of bound and free [3H]FMLP were analyzed assuming the relationship: kf
kr Because kr < Kf in this system, we may ignore the dissociation reaction during the brief time-course of these experiments. To confirm that the reaction follows second order kinetics, several experiments were also analyzed using the general solution for the second order reaction; (33) . Granulocyte aggregation. Granulocyte aggregation was performed as described (1) . 50 ,ul zymosan-activated plasma or FMLP, in PBS, was added to 450 I1A of a granulocyte suspension (1.1 x 107 cells/ml in HBSS), which was being stirred at 700 rpm in a Payton 300B aggregometer/recorder system (Payton Associates, Buffalo, N. Y.). After 2 min, 50 A1 of corticosteroid solution in PBS was added. The resulting light transmittance was recorded on a stripchart recorder. The state of granulocyte aggregation was also confirmed by light microscopy of aliquots taken from the aggregometer before and after addition of corticosteroid.
RESULTS
In vivo induction ofneutropenia with FMLP. Intravenous infusion of FMLP into rabbits mimicked the effects of similar infusions of activated plasma complement. Following the initiation of a constant infusion of FMLP, there was a prompt neutropenia (as reported with bolus infusion) (25) with the PMN count falling to a mean 20% of the preinfusion value, and then rising to a preinfusion level by 30 min despite continued FMLP infusion (Fig. 1) . The transience of the neutropenia is attributed to the development of granulocyte refractoriness to repeated stimulation, as we have shown in hemodialysis and in vitro with both CSa and FMLP (34, 35) . Kinetic analysis of FMLP binding. HC, MP, and DEX inhibited binding of FMLP to the granulocyte surface whereas sodium succinate alone had no effect. Hydrocortisone phosphate blocked [3H]FMLP binding with a potency similar to HC. Inhibition of binding was dose dependent, and the order of potency in receptor blockade (MP > HC > DEX) was the same as that observed in aggregation blockade (7) , markedly different from the order of potency observed using classical assays of corticosteroid effect (36) (Fig. 2 ). Examination of [3H]FMLP binding at varying [3H]-FMLP concentrations in the presence and absence of 0.2 mg/ml MP did not reveal a decrease in the number of surface FMLP receptors in the presence of MP, although the apparent equilibrium binding constant is clearly reduced by MP (Fig. 3 ). Sips analysis (28) (29) (30) of the binding of [3H]FMLP to granulocytes at 37°C in the presence and absence of 0.2 mg/ml MP gave a Keq value of 3.4 x 107/M in the absence of MP and 1.6 x 107/M in the presence of 0.2 mg/ml MP (Fig.  4) . Similar experiments were performed at 40C to prevent internalization of peptide-receptor complexes. As reported (37), we found more [3H]FMLP binding at 37°C than at 4°C, likely due to peptide internalization. Scatchard analysis of equilibrium binding of sociation following the addition of excess unlabeled FMLP was the same as that observed following addition of NIP to a final concentration of 5 mg/mil (Fig. 6 ). The kr observed in the presence of excess unlabeled FMLP was 1.32±+ 0.31 (SD) x 10-3/s (it = 6) and 1.34±+ 0.26 (SD) x 10-3/s (n1 = 4) in the presence of 5 mg/ml MP.
Simultaneous addition of 5 mg/ml MP and excess unlabeled FMLP produced identical results (not shown). Identical experiments were performed in the presence of 10 mM NaN3 and 10 mM 2-deoxy-D-glucose following a 30-min preincubation of graniulocytes in the same concentration of azide and 2-deoxy-D-glucose. This protocol was intended to prevent internalization of receptor-peptide complexes and thus to eliminate the possibility that some of the observed displacement of bound radioactivity was due to intracellular degradation and release of previously internalized peptidereceptor complexes. These experiments again revealed no difference in the rate of displacement of bound radioactivity in the presence of excess unlabeled FMLP as compared with 5 mg/ml MP. Furthermore, under these conditions >85% of the initial cell-bound counts were displaceable with a kr of 8.6 x 10-4/s and 6.4 x 10-4/s (mean of two experiments) in the presence of 5 mg/ml MP or excess unlabeled FMLP, respectively. We also studied dissociation kinetics at 40C, following incubation of neutrophils with receptor saturating concentrations of [3H]FMLP for 20 min at 4°C, as a further control for intemalization of receptor-bound peptide (38, 39) . As at 37°C, not all bound [3H]FMLP dissociates from the cell at the same rate. When dissociation was induced by 5 [3H]FMLP dissociated with an apparent kr of 3 x 10-2/s and >20% dissociated with an apparent k, of 6.5
x 10-4/s. When dissociation was induced by 10 gM unlabeled FMLP, -40% of the bound [3H]FMLP dissociated with an apparent kr of 3 x 10-2/s and an additional 30% with an apparent kr of 10-3/S. Thus, although the observed kr was greater at 4°C than 37°C, perhaps due to peptide internalization, 5 mg/ml MP and excess unlabeled FMLP both displaced bound [3H]FMLP at similar rates.
Associatiotn kitnetics of FMLP binding. Analysis of association data as a second order association reaction as described above yielded a straight line, confirming second order kinetics. To simplify the analysis, further experiments were performed under conditions yielding pseudo-first order kinetics in the presence of a 10-fold excess concentration of peptide over receptor (Fig. 7) . A single class of forward rate constants is suggested by the linearity of the plot both in the presence and absence of 0. cell lysis during aggregation and subsequent corticosteroid-induced disaggregation, and the cells maintained the ability to exclude trypan blue (>95% viable). As in the case of FMLP binding and corticosteroid blockade of aggregation, corticosteroid-induced disaggregation was dose related, both with respect to corticosteroid and aggregating stimulus. The observed order of potency as inducers of disaggregation was again MP > HC > DEX, the same as reported for inhibition of aggregation.
DISCUSSION
Since the introduction of corticosteroids into clinical medicine three decades ago they have been found effective in the treatment of a wide variety of disorders, and much has been written about their mechanism of action. In contrast to the modest doses of these agents used in replacement therapy and in the treatment of chronic immune disorders, very high-dose (30 mg/kg i.v.) corticosteroid therapx has recently been reported to be of benefit in the tre oment of endotoxic shock and the adult respiratory distress syndrome (12) (13) (14) (15) (16) . It seems likely that the effects of these agents at very high doses might be different from those observed at low doses; in fact, several mechanisms for antiinflammatory action of corticosteroids have been reported, and the concentration ranges at which they are effective differ.
In vivo studies of immune hemolytic anemia suggested corticosteroid treatment in some way altered the interaction between the target erythrocytes and receptors on the surface of the effector reticuloendothelial cell (41) (42) (43) . Other in vitro and in vivo studies have also implicated an impairment of binding of C3b and IgG to their respective receptors on monocyte/ macrophages (20, 21) , and more recently neutrophils (22, 23) , to be one effect of supraphysiologic concentrations (0.05-1.0 mg/ml) of corticosteroids. Recently, using the HL-60 human progranulocytic cell line, it has been demonstrated that 200 nM DEX decreased the number of Fc receptors for IgG expressed on the surface of the myeloid cells without significantly altering the receptor affinity for its ligand (44) and with no gross decrease in protein synthesis. We recently reported that high-dose corticosteroids blocked PMN aggregation in vivo and in vitro (7) . We now have examined the effect of corticosteroids on the binding of the synthetic chemotaxin FMLP to its receptor on human granulocytes because previous in vitro and in vivo studies of PMN responses to chemotactic stimuli (25, 35, 45, 46) , as well as the in vivo response to FMLP infusion, suggested FMLP is a reasonable model for CSa-induced PMN leukostasis and tissue injury.
The mechanism by which peptide binding is altered by corticosteroids was further elucidated by examining the kinetics of interaction of the peptide with its receptor using living whole granulocytes. MP displaced bound radiolabeled FMLP from granulocytes at the same rate as an excess of unlabeled FMLP, suggesting that MP did not alter the rate of dissociation ofFMLP from its surface receptor. Because a significant fraction of radiolabel remained cell associated in these experiments, internalization of peptide was a possibility (as has been recently described) (37) (38) (39) (40) . We therefore sought to prevent [3H]FMLP internalization by performing similar experiments at 40C and by using conditions found to prevent internalization of other receptor ligand complexes in other cell lines (32, 40) . The observed rates of peptide displacement were similar under both conditions, providing further evidence that MP does not alter the dissociation rate constant. In contrast, when the association rate constant was examined, we found 0.2 mg/ml MP decreases kf by -65%.
The mechanism by which corticosteroids alter the receptor-ligand interaction remains unknown. Steroids have been shown to alter membrane fluidity, and the potency of several steroid anesthetics has been shown to correlate with their ability to disorder (increase the molecular freedom of) the hydrocarbon core of lipid bilayers, as measured by electron spin resonance (47) . The molecular nature of the FMLP receptor has not been well characterized, but it is quite possible that alterations in membrane fluidity, induced by corticosteroids, could alter surface expression of the receptor or interaction of receptor subunits resulting in a decrease in affinity for the ligand.
We also examined the ability of corticosteroids to cause disaggregation of granulocyte aggregates. We found in vitro corticosteroids cause rapid disaggregation ofgranulocyte aggregates engendered by zymosanactivated plasma or FMLP in the same concentration range that blocks receptor binding. Furthermore, disaggregation was dose dependent, both with respect to concentration of corticosteroid and to that of aggregation stimulus.
We conclude that high-dose corticosteroids can cause disaggregation of previously aggregated granulocytes as well as block granulocyte aggregation. Furthermore, these same concentrations ofcorticosteroids alter binding of the synthetic chemotaxin, [3H]FMLP, to its specific receptor on the neutrophil surface. This alteration in receptor binding is due primarily to a decrease in the association rate constant for peptide-receptor interaction without significant change in dissociation rate or receptor number. A prominent effect on the FMLP-receptor interaction is observed at MP concentrations of 1 mg/ml (Fig. 2) , a level approximating the plasma concentration immediately after a 30-mg/kg i.v. bolus, and a substantial effect is seen at even lower concentrations. Furthermore, at lower stimulus concentrations the level of corticosteroid required for effect is less, suggesting that a similar effect might be observed in some clinical situations with even lower corticosteroid concentrations. Receptor alteration may therefore be an important aspect of the effects of highdose corticosteroids on granulocyte aggregation. Similarly, alteration of receptors on other cells for other mediators (for example C5a on endothelial cells) may also contribute to the reported efficacy of high-dose corticosteroids in other clinical syndromes.
